Version July 2025
| Agent | Dosing frequency and timing in relation to food | Dose adjustments for baseline kidney/liver dysfunction | Major toxicities | Other |
| Imatinib | Daily (or twice daily) with food | Yes (kidney, liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hepatotoxicity. | Longest record of safety data |
| Nilotinib | Taken twice daily. Note that there are two formulations (ie, a tablet that can be taken with food and a capsule that cannot be taken with food). The two formulations cannot be substituted milligram-for-milligram, and dosing varies with the treatment setting. | Yes (liver) | Bone marrow suppression; cardiovascular events; electrolyte imbalance; hepatotoxicity. Boxed warning: QT prolongation (screening required). | |
| Dasatinib | Daily with or without food | No | Bone marrow suppression; pleural/pericardial effusions; pulmonary arterial hypertension; QT prolongation; aspirin-like effect. | |
| Bosutinib | Daily with food | Yes (kidney, liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects. | |
| Ponatinib | Daily with or without food | Yes (liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hypertension; pancreatitis; aspirin-like effect; arterial thrombosis. Boxed warning: cardiovascular events; hepatotoxicity. | Active against BCR::ABL1 T315I mutation; limited long-term safety data. |
| Asciminib | Daily or twice daily without food | No | Upper respiratory tract infections; musculoskeletal pain; fatigue; nausea; rash; and diarrhea. Hypertriglyceridemia; cytopenias; elevated creatine kinase; hepatotoxicity; pancreatitis. | Active against BCR::ABL1 T315I mutation; limited long-term safety data. |
